Sanuwave Announces Revenues and Financial Results for Q1 FY2026
Sanuwave Health, Inc. reported Q1 2026 revenue of $9.6 million, up 3.1% from $9.3 million in Q1 2025. This marks the highest Q1 revenue in the company's history. Gross margin decreased to 77.3% from 79.0% in Q1 2025, primarily due to lower pricing on Ultramist® systems and applicators from wholesale sales to resellers.
Key figures
- Revenue
- 9619000
- Guidance
- Q2 2026 revenue $11.1M-$11.6M (10-15% increase from Q2 2025); full year 2026 revenue $51.0M-$55.0M (16-25% increase from full year 2025)
- Revenue Yoy
- 3.1%
- Gross margin
- 77.3%
- Adjusted ebitda
- 1089000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.